NASDAQ · ABIO
Healthcare · Biotechnology
$28.80
Up+$26.30 (+1052.00%)
Updated Sep 16, 2026, 12:07 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ABIO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ABIO.
ABIO research
Company profile and research snapshot.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 29, 2024
ARCA biopharma has completed a merger with Oruka Therapeutics and will implement a 1-for-12 reverse stock split. The combined company will operate under the name Oruka Therapeutics and trade on Nasdaq under the ticker 'ORKA'.
GlobeNewswire Inc. · Aug 26, 2024
ARCA biopharma announced an update to the previously announced final amount of the special cash dividend, which will now equal $1.613 per share, payable on August 28, 2024. The special dividend is in connection with the proposed merger between ARCA and Oruka Therapeutics, which is expected to close on August 29, 2024.
GlobeNewswire Inc. · Apr 25, 2024
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc. · Apr 3, 2024
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABIO.
No results
No recent SID articles mention ABIO.
